Yuhan Corporation
Clinical trials sponsored by Yuhan Corporation, explained in plain language.
-
New pill targets Tough-to-Treat cancers in groundbreaking trial
Disease control Recruiting nowThis early-stage study is testing a new oral medication called YH42946 for people with advanced solid tumors that have specific genetic changes (HER2 or EGFR mutations). The trial aims to find the safest dose and see if the drug can shrink tumors in 161 patients who have run out …
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
First patients receive novel Two-Target cancer drug in global trial
Disease control Recruiting nowThis is the first time researchers are testing a new drug called YH32367 in people. The study aims to find a safe and effective dose for patients with advanced HER2-positive cancers that have spread or cannot be removed by surgery. The drug is designed to attack cancer cells in t…
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
First human doses given for rare brain disease treatment
Knowledge-focused Recruiting nowThis is the first study to test a new oral drug, called YH35995, in people. The goal is to check its basic safety and how the body processes it in healthy male volunteers. This is an early, necessary step to see if the drug could later help treat the brain-related symptoms of a r…
Phase: PHASE1 • Sponsor: Yuhan Corporation • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC